#Japan #Myasthenia Gravis #Minato-ku, Tokyo #Klygefa #Alexion Pharma

Klygefa®: A Breakthrough in the Treatment of gMG

In a significant advancement, Alexion Pharma LLC has announced that Klygefa® (generic name: gefurulimab) has received manufacturing and marketing authorization in Japan for use as a treatment for adult patients with generalized myasthenia gravis (gMG). This approval marks Klygefa as the first dual-binding nanobody C5 inhibitor specifically aimed at gMG, a rare autoimmune disorder characterized by severe muscle weakness.

The approval by the Ministry of Health, Labour and Welfare is based on favorable outcomes from the Phase III clinical trial known as PREVAIL, with results presented at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and published in JAMA Neurology.

Understanding Generalized Myasthenia Gravis (gMG)

Generalized myasthenia gravis is an autoimmune disorder that impairs communication between nerves and muscles, leading to debilitating symptoms such as fluctuating muscle weakness, including difficulty in speaking, vision issues, and severe fatigue. The estimated patient population in Japan is around 21,000, with approximately 18,000 of them testing positive for anti-acetylcholine receptor (AChR) antibodies.

As the disease progresses, symptoms can become more severe, including difficulties in swallowing and breathing. This progression can greatly impact patients' quality of life.

The PREVAIL Study: Groundbreaking Results

The PREVAIL trial was a multi-center, randomized, double-blind, placebo-controlled study that assessed the safety and efficacy of Klygefa in 260 adult patients across North America, Europe, Asia, and the Pacific. The trial's primary endpoint was the change in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, which demonstrated significant improvement compared to placebo at week 26.

Specifically, Klygefa showed a notable reduction in the MG-ADL total score at 26 weeks, compared to the baseline (treatment group difference: -1.6, p<0.0001). Improvements were seen as early as Week 1, maintaining through the study's conclusion. Safety data indicated that adverse side effects were similar between the Klygefa and placebo groups, primarily consisting of mild to moderate reactions.

Expert Insights and Future Implications

Dr. Masanobu Masuda, a trial investigator from Tokyo Medical University, noted the substantial impact of gMG symptoms on patients' daily lives, and emphasized the potential of Klygefa's once-weekly self-injection regimen in providing greater autonomy and treatment flexibility. The introduction of Klygefa aims to reduce the disease burden linked with gMG and enhance patients' overall quality of life.

Mark Duquenois, CEO of Alexion AstraZeneca Rare Diseases, expressed optimism, stating that Klygefa embodies the company's commitment to advancing treatments for gMG patients and enabling better symptom management.

The PREVAIL trial's findings will further support efforts for manufacturing approval applications in various countries, including the U.S. and the EU, paving the way for more patients globally to benefit from this novel treatment option.

Conclusion

Klygefa® represents a significant development in the management of generalized myasthenia gravis, offering patients a new therapeutic choice that aligns with current practice needs. The introduction of this novel dual-binding nanobody reflects Alexion's dedication to addressing the unmet needs in rare diseases and advancing patient outcomes.

For more information on Klygefa and gMG, visit Alexion Pharma's official site.

This groundbreaking treatment promises not only to control symptoms effectively but also to improve the quality of life for many who struggle with this challenging condition.